KORELASI ANTARA KADAR PROKALSITONIN DAN MYELOPEROXIDASE INDEX PADA PASIEN SEPSIS

Sri Rejeki Wulandari, Betty Agustina Tambunan, Paulus Budiono Notopuro, Hardiono Hardiono

Abstract


Sepsis masih menjadi masalah utama di dunia. Europan Society of Intensive Care Medicine (ESICM) dan Society of Critical Care Medicine (SCCM) mengikutsertakan quick Sequential Organ Failure Asssessment  (qSOFA) untuk mendiagnosis sepsis. Diperlukan pemeriksaan laboratorium akurat dan cepat selain kultur. Prokalsitonin sebagai penanda spesifik infeksi bakteri. Myeloperoxidase index (MPXI) parameter baru untuk membantu diagnosis sepsis. Penelitian ini bertujuan menganalisis korelasi kadar prokalsitonin dengan MPXI pada pasien sepsis.  Jenis penelitian cross sectional observasional. Pengambilan sampel Desember 2017  – Februari 2018. Subjek penelitian terdiri dari 71 pasien sepsis yang dirawat di Ruang Resusitasi, Ruang Observasi Intensif, dan ruang Intensive Care Unit (ICU) RSUD Dr. Soetomo Surabaya berdasarkan kriteria qSOFA dan SIRS. Pemeriksaan prokalsitonin dengan metode CLIA (ADVIA Centaur XP), MPXI dengan  metode  flowcytometry (ADVIA 2120i) dan kultur menggunakan alat PhoenixTM 100. Kadar prokalsitonin 0,01 ng/mL – 265,16 ng/mL (rerata 16,13 ± 40,91 ng/mL). Nilai MPXI -25,5 – 4,6 (rerata -7,939 ± 4,903). Tidak terdapat korelasi antara kadar prokalsitonin dengan MPXI ( p = 0,604 dan r = - 0,063). Tidak terdapat  korelasi kadar prokalsitonin dengan MPXI pada hasil  kultur positif (p = 0,675, r = 0,072) dan negatif (p = 0,401, r = - 0,147). Kadar prokalsitonin tidak berkolerasi dengan MPXI pada pasien sepsis


Keywords


Sepsis, prokalsitonin, MPXI

References


Dellinger RP, Levy MM, Rhodes A, et al. 2013. Surviving Sepsis Campaign Guidelines Committee Including the Pediatric Subgroup. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med; 41(2):580-637.

Warden K. 2001. Pathophysiology of Septic Shock and Multiple Organ Dysfunction Syndrome and Various Therapeutic Approaches with Special Emphasis on Immunoglobulins. Ther Apher, Vol. 5;2. p; 115-122.

Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM,Knaus WA, et al. 1992. Definitions of sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 2009; 136(5 suppl):e28.

Martin GS. 2012. Sepsis, severe sepsis and septic shock: changes in incidence, pathogens and outcomes. Expert Review of Anti-infective therapy;10(6):701–6.

Taty E, 2009. ‘Penatalaksanaan syok septik pada anak’ Dalam simposium Nasional Perinatologi dab Pediatri Gawat Darurat, Banjarmasin, IDAI Kalimantan selatan.

Mayr FB et al, 2014. Epidemiology of severe sepsis. Virulence 5:1, 4–11.

Bone RC, Balk RA, Cerra FB, et al. Defi nitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644–55.

Ross D.W. & Bentley S.A. (1986) Evaluation of an automated hematology system (Technicon H-1). Archives of Pathology and Laboratory Medicine 110, 803–808.

Cha YS, et al. 2014. Evaluation of usefulness of myeloperoxidase index (MPXI) for differential diagnosis of systemic inflammatory response syndrome (SIRS) in the emergency department. Emerg Med J;32:304–307.

Esper, AM., Moss, M., Lewis, CA., Nisbet, R., Mannino, DM., Martin, GS., 2006. The Role of Infection and Comorbidity: Factors That Influence Disparities in Sepsis. Critical Care Medicine, 34(10), pp.2576-82.

Angele MK, Pratschke S, Hubbard WJ, Chaudry IH. Gender differences in sepsis: cardiovascular and immunological aspects. Virulence 2014;5:12-9.

Iskander, KN., Osuchowski, MF., Stearns-Kurosawa, DJ., Kurosawa, S., Stepien, D., Valentine, C., Remick, DG., 2013. Sepsis: Multiple Abnormalities, Heterogenous Responses, and Evolving Understanding. Physiological Reviews, 93, pp.1247-88.

Arifijanto M V. 2015. Sepsis. In A. Tjokropprawiro A et al., eds. Buku Ajar Ilmu Penyakit Dalam. 2nd ed. Surabaya: Airlangga University Press. pp.701-707.

Ma’at, Suprapto, 2012. Inflamasi. Pusat Penerbitan dan Percetakan UNAIR (AUP). Edisi 1. Hal 18.

Stearns-Kurosawa, DJ., Osuchowski, MF., Valentine, C., Kurosawa, S., Remick, DG., 2011. ‘The Pathogenesis of Sepsis’. Annual Review of Pathology Mechanisms of Disease, 6, pp.19-48.

Nimmo JR, 2006. Identifiying Sepsis Early. Learning Technology Section, The University of Edinburgh, p; 1-18.

Munford, R. S., 2001. "Sepsis and septic shock". Dalam: E. Braundwald, penyunt. Harrison's Principles of Internal Medicine. New York: Mc Graw-Hill, pp. 799-804.

Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med 2013; 369:840-51.

Nasronudin, 2011. ‘Imunopatogenesis Sepsis dan Prinsip Penatalaksanaan. In Penyakit Infeksi di Indonesia: Solusi Kini dan Mendatang. 2nd ed. Surabaya’: Airlangga University Press. pp.320-24.

Phua J, Ngerng WJ, See KC, Tay CK, Kiong T, et al. Characteristics and outcomes of culture-negative versus culture positive severe sepsis. Critical care 3013 17:R202. doi:10.1186/cc12896.

Artero, A, Zaragoza, R, Noguiera, JM., 2013. "Epidemiology severe sepsis and shock sepsis", Valencia: Universitat de Valencia.

Hefner, AM., Norton, JM., Marchick, MM. Jones, AE., 2010. "Etiology of illness in patients with severe sepsis admitted to the hospital from the emergency department". Clinical Infectious Diseases, 50(6), pp. 814-820.

Schuetz P, Chiappa V, Briel M, Greenwald JL. Procalcitonin algorithms for antibiotic therapy decisions. Arch Intern Med. 2011;171(15):1322-1331.

Kibe S et al. 2011 Diagnostic And Prognostic Biomarkers Of Sepsis In Critical Care. J Antimicrob Chemother 2011; 66 Suppl 2: ii33–ii40.

Meisner M. 2010. Procalcitonin Biochemistry and Clinical Diagnosis. Uni-Med. 1st ed. Bremen; pp. 9-16.

Nargis W, Ibrahim M, Ahamed BU. Procalcitonin versus Creactive protein: Usefulness as biomarker of sepsis in ICU patient. International Journal of Critical Illness and Injury Science 2014;4(3):195–9.

Shehabi Y, Seppelt I. Pro/con debate: is procalcitonin useful for guiding antibiotic decision making in critically ill patients? Crit Care 2008; 12: 211–6.

Bouadma L, Luyt C-E, Tubach F et al. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010; 375: 463–74.

Cassado-flores J, Blanco-Quiros A, Asensio J, Arranz E, Garrote J, Nieto M, 2003. Serum procalcitonin in children with suspected sepsis: A Comparison with C-reactive protein and neutrophil count. Pediatric Critical Care Medicine, 4(2): 190-195.

Reinhart K, Karzai W, Meisner M. Procalcitonin as a systemic inflammatory response to infection. Intensive Care Med 2000; 26: 1193–200.

R. H. Snider Jr., E. S.Nylen, and K. L. Becker, “Procalcitonin and its component peptides in systemic inflammation: immunochemical characterization,” Journal of Investigative Medicine, vol. 45, no. 9, pp. 552–560, 1997.

Yonezawa K et al. Association between the neutrophil myeloperoxidase index and subsets of bacterial infections. Lab. Hem. 2010, 32, 598–605.

Buffon, A., Biasucci, L.M., Liuzzo, G., D´ Onofrio, G., Crea, F., Maseri, A., 2002. Widespread coronary inflammation in unstable angina. New England Journal of Medicine 347, 5–12

Grulke, S., Franck, T., Gangl, M., Peters, F., Salciccia, A., Deby-Dupont, G., Serteyn, D., 2008. Myeloperoxidase assay in plasma and peritoneal fluid of horses with gastrointestinal disease. Canadian Journal of Veterinary Research 72, 37–42.

Handojo I, 2004. Imunoasai Terapan pada Beberapa Penyakit Infeksi. Airlangga University Press, halaman: 272-285.

Vijayan et al. Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy. Journal of Intensive Care 2017. p 5:51.




DOI: http://dx.doi.org/10.24293/ijcpml.v25i3.1451

Refbacks

  • There are currently no refbacks.